Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease
- 1 July 2006
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 2 (4) , 649-658
Abstract
The 12/15-lipoxygenase (LO) cascade governs the generation of 12-hydroperoxy-eicosatetraenoic acid (HPETE) and 15-HPETE from arachidonic acid. The 5-LO pathway plays a fundamental role in the biosynthesis of leukotrienes, essential inflammatory lipid mediators. Cyclooxygenase (COX)-1 and -2 biosynthetic pathways are responsible for prostaglandin and thromboxane formation. Experimental investigations in animal models using 12/15-LO deficient mice, 12/15-LO or 15-LO transgenic mice, or pharmacological 15-LO inhibition have all demonstrated the essential role of 12/15-LO in atherogenesis. The underlying mechanisms are linked to low-density lipoprotein oxidation, pro-inflammatory Th1 cytokine production and enhanced monocyte–endothelial cell interaction. Human genetic studies as well as disruption of the 5-LO gene in mouse models of hyperlipidemia revealed that 5-LO and 5-LO-activating protein are associated with risks of human cardiovascular disease, and that this cascade plays an important role in aortic aneurysm pathogenesis through leukotriene-mediated inflammatory chemokine production. COX-1 plays an active role in atherogenesis via thromboxane A2, while COX-2-derived prostaglandin (PGI2) protects against atherosclerosis in murine models. Recent data demonstrated that selective inhibition of COX-2 augments the risk of cardiovascular events in patients. Selective inhibition or blockade of selective components in these two enzymatic pathways through systemic drug delivery or medical device approaches (e.g., drug-eluting stents) may have therapeutic benefit against certain cardiovascular diseases.Keywords
This publication has 100 references indexed in Scilit:
- 12/15-Lipoxygenase gene disruption and Vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathwayProstaglandins & Other Lipid Mediators, 2005
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell RecruitmentCirculation, 2005
- ALOX5AP Gene and the PDE4D Gene in a Central European Population of Stroke PatientsStroke, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Association between the Gene Encoding 5-Lipoxygenase–Activating Protein and Stroke Replicated in a Scottish PopulationThe American Journal of Human Genetics, 2005
- Inflammation in atherosclerosisNature, 2002
- The Murine Cysteinyl Leukotriene 2 (CysLT2) ReceptorJournal of Biological Chemistry, 2001
- The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient miceBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996